Reported 2 days ago
JonesResearch analyst Soumit Roy has reduced the price target for Enliven (ELVN) from $36 to $27 while maintaining a Buy rating. The adjustment comes after a lukewarm market reaction to the company's Phase 1 chronic myeloid leukemia trial results for ELVN-001, despite its efficacy. The analysis suggests that the stock has faced a sell-off reaction following the news.
Source: YAHOO